New strategies in the treatment of early Parkinson's disease
Identifieur interne : 002C19 ( Main/Corpus ); précédent : 002C18; suivant : 002C20New strategies in the treatment of early Parkinson's disease
Auteurs : U. K. RinneSource :
- Acta Neurologica Scandinavica [ 0001-6314 ] ; 1991-10.
English descriptors
- KwdEn :
Abstract
Over recent years I have been studying whether dopamine agonist treatment alone, or in early combination with levodopa, might institute a better long‐term treatment in Parkinson's disease than levodopa alone. Indeed, early combination of levodopa with bromocriptine, pergolide or lisuride has indicated that this kind of treatment results in better management of Parkinson's disease with fewer fluctuations in disability, especially end‐of‐dose disturbances and dyskinesias, than treatment with levodopa alone. Furthermore, similar results were obtained by using lisuride in combination with selegiline and levodopa. However, during long‐term treatment the changes in parkinsonian disability were equal in all treatment groups with or without selegiline. Thus, the possible efficacy of selegiline in slowing down the progression of Parkinson's disease requires further investigations. As a new treatment strategy it appears advisable to initiate the dopaminergic treatment in early Parkinson's disease by using initially selegiline and a dopamine agonist and by adding levodopa when the therapeutic response is insuifficient. Another alternative would be to start with selegiline alone, then add a dopamine agonist and, finally, levodopa.
Url:
DOI: 10.1111/j.1600-0404.1991.tb05028.x
Links to Exploration step
ISTEX:606CF73F0EA47D7B6C3F1CDA414B291234905B43Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">New strategies in the treatment of early Parkinson's disease</title><author><name sortKey="Rinne, U K" sort="Rinne, U K" uniqKey="Rinne U" first="U. K." last="Rinne">U. K. Rinne</name><affiliation><mods:affiliation>Department of Neurology, University of Turku, Turku, Finland</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:606CF73F0EA47D7B6C3F1CDA414B291234905B43</idno><date when="1991" year="1991">1991</date><idno type="doi">10.1111/j.1600-0404.1991.tb05028.x</idno><idno type="url">https://api.istex.fr/document/606CF73F0EA47D7B6C3F1CDA414B291234905B43/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002C19</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">New strategies in the treatment of early Parkinson's disease</title><author><name sortKey="Rinne, U K" sort="Rinne, U K" uniqKey="Rinne U" first="U. K." last="Rinne">U. K. Rinne</name><affiliation><mods:affiliation>Department of Neurology, University of Turku, Turku, Finland</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Acta Neurologica Scandinavica</title><idno type="ISSN">0001-6314</idno><idno type="eISSN">1600-0404</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1991-10">1991-10</date><biblScope unit="volume">84</biblScope><biblScope unit="issue">S136</biblScope><biblScope unit="page" from="95">95</biblScope><biblScope unit="page" to="98">98</biblScope></imprint><idno type="ISSN">0001-6314</idno></series><idno type="istex">606CF73F0EA47D7B6C3F1CDA414B291234905B43</idno><idno type="DOI">10.1111/j.1600-0404.1991.tb05028.x</idno><idno type="ArticleID">ANE95</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0001-6314</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>dopamine agonist</term><term>early treatment</term><term>levodopa</term><term>new strategies</term><term>selegiline</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Over recent years I have been studying whether dopamine agonist treatment alone, or in early combination with levodopa, might institute a better long‐term treatment in Parkinson's disease than levodopa alone. Indeed, early combination of levodopa with bromocriptine, pergolide or lisuride has indicated that this kind of treatment results in better management of Parkinson's disease with fewer fluctuations in disability, especially end‐of‐dose disturbances and dyskinesias, than treatment with levodopa alone. Furthermore, similar results were obtained by using lisuride in combination with selegiline and levodopa. However, during long‐term treatment the changes in parkinsonian disability were equal in all treatment groups with or without selegiline. Thus, the possible efficacy of selegiline in slowing down the progression of Parkinson's disease requires further investigations. As a new treatment strategy it appears advisable to initiate the dopaminergic treatment in early Parkinson's disease by using initially selegiline and a dopamine agonist and by adding levodopa when the therapeutic response is insuifficient. Another alternative would be to start with selegiline alone, then add a dopamine agonist and, finally, levodopa.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>U. K. Rinne</name><affiliations><json:string>Department of Neurology, University of Turku, Turku, Finland</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>early treatment</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>new strategies</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>selegiline</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dopamine agonist</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>levodopa</value></json:item></subject><articleId><json:string>ANE95</json:string></articleId><language><json:string>eng</json:string></language><abstract>Over recent years I have been studying whether dopamine agonist treatment alone, or in early combination with levodopa, might institute a better long‐term treatment in Parkinson's disease than levodopa alone. Indeed, early combination of levodopa with bromocriptine, pergolide or lisuride has indicated that this kind of treatment results in better management of Parkinson's disease with fewer fluctuations in disability, especially end‐of‐dose disturbances and dyskinesias, than treatment with levodopa alone. Furthermore, similar results were obtained by using lisuride in combination with selegiline and levodopa. However, during long‐term treatment the changes in parkinsonian disability were equal in all treatment groups with or without selegiline. Thus, the possible efficacy of selegiline in slowing down the progression of Parkinson's disease requires further investigations. As a new treatment strategy it appears advisable to initiate the dopaminergic treatment in early Parkinson's disease by using initially selegiline and a dopamine agonist and by adding levodopa when the therapeutic response is insuifficient. Another alternative would be to start with selegiline alone, then add a dopamine agonist and, finally, levodopa.</abstract><qualityIndicators><score>5.173</score><pdfVersion>1.5</pdfVersion><pdfPageSize>587.519 x 793.919 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>6</keywordCount><abstractCharCount>1238</abstractCharCount><pdfWordCount>2121</pdfWordCount><pdfCharCount>14129</pdfCharCount><pdfPageCount>4</pdfPageCount><abstractWordCount>171</abstractWordCount></qualityIndicators><title>New strategies in the treatment of early Parkinson's disease</title><genre><json:string>article</json:string></genre><host><volume>84</volume><publisherId><json:string>ANE</json:string></publisherId><pages><total>4</total><last>98</last><first>95</first></pages><issn><json:string>0001-6314</json:string></issn><issue>S136</issue><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1600-0404</json:string></eissn><title>Acta Neurologica Scandinavica</title><doi><json:string>10.1111/(ISSN)1600-0404</json:string></doi></host><publicationDate>1991</publicationDate><copyrightDate>1991</copyrightDate><doi><json:string>10.1111/j.1600-0404.1991.tb05028.x</json:string></doi><id>606CF73F0EA47D7B6C3F1CDA414B291234905B43</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/606CF73F0EA47D7B6C3F1CDA414B291234905B43/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/606CF73F0EA47D7B6C3F1CDA414B291234905B43/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/606CF73F0EA47D7B6C3F1CDA414B291234905B43/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">New strategies in the treatment of early Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>WILEY</p></availability><date>1991</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">New strategies in the treatment of early Parkinson's disease</title><author><persName><forename type="first">U. K.</forename><surname>Rinne</surname></persName><note type="correspondence"><p>Correspondence: Urpo K, Rinne, Department of Neurology, University of Turku SF‐20520 Turku, Finland</p></note><affiliation>Department of Neurology, University of Turku, Turku, Finland</affiliation></author></analytic><monogr><title level="j">Acta Neurologica Scandinavica</title><idno type="pISSN">0001-6314</idno><idno type="eISSN">1600-0404</idno><idno type="DOI">10.1111/(ISSN)1600-0404</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1991-10"></date><biblScope unit="volume">84</biblScope><biblScope unit="issue">S136</biblScope><biblScope unit="page" from="95">95</biblScope><biblScope unit="page" to="98">98</biblScope></imprint></monogr><idno type="istex">606CF73F0EA47D7B6C3F1CDA414B291234905B43</idno><idno type="DOI">10.1111/j.1600-0404.1991.tb05028.x</idno><idno type="ArticleID">ANE95</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1991</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Over recent years I have been studying whether dopamine agonist treatment alone, or in early combination with levodopa, might institute a better long‐term treatment in Parkinson's disease than levodopa alone. Indeed, early combination of levodopa with bromocriptine, pergolide or lisuride has indicated that this kind of treatment results in better management of Parkinson's disease with fewer fluctuations in disability, especially end‐of‐dose disturbances and dyskinesias, than treatment with levodopa alone. Furthermore, similar results were obtained by using lisuride in combination with selegiline and levodopa. However, during long‐term treatment the changes in parkinsonian disability were equal in all treatment groups with or without selegiline. Thus, the possible efficacy of selegiline in slowing down the progression of Parkinson's disease requires further investigations. As a new treatment strategy it appears advisable to initiate the dopaminergic treatment in early Parkinson's disease by using initially selegiline and a dopamine agonist and by adding levodopa when the therapeutic response is insuifficient. Another alternative would be to start with selegiline alone, then add a dopamine agonist and, finally, levodopa.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>early treatment</term></item><item><term>new strategies</term></item><item><term>selegiline</term></item><item><term>dopamine agonist</term></item><item><term>levodopa</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1991-10">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/606CF73F0EA47D7B6C3F1CDA414B291234905B43/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1600-0404</doi><issn type="print">0001-6314</issn><issn type="electronic">1600-0404</issn><idGroup><id type="product" value="ANE"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="ACTA NEUROLOGICA SCANDINAVICA">Acta Neurologica Scandinavica</title></titleGroup></publicationMeta><publicationMeta level="part" position="10000"><doi origin="wiley">10.1111/ane.1991.84.issue-S136</doi><numberingGroup><numbering type="journalVolume" number="84">84</numbering><numbering type="journalIssue">S136</numbering></numberingGroup><coverDate startDate="1991-10">October 1991</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="0009500" status="forIssue"><doi origin="wiley">10.1111/j.1600-0404.1991.tb05028.x</doi><idGroup><id type="unit" value="ANE95"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="tocHeading1">Original article</title></titleGroup><copyright>1991 Blackwell Munksgaard</copyright><eventGroup><event type="firstOnline" date="2009-01-29"></event><event type="publishedOnlineFinalForm" date="2009-01-29"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.6 mode:FullText source:HeaderRef result:HeaderRef" date="2010-04-20"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:4.0.1" date="2014-03-15"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="95">95</numbering><numbering type="pageLast" number="98">98</numbering></numberingGroup><correspondenceTo>Urpo K, Rinne, Department of Neurology, University of Turku SF‐20520 Turku, Finland</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ANE.ANE95.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="referenceTotal" number="26"></count><count type="linksCrossRef" number="2"></count></countGroup><titleGroup><title type="main">New strategies in the treatment of early Parkinson's disease</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1" corresponding="yes"><personName><givenNames>U. K.</givenNames><familyName>Rinne</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="FI"><unparsedAffiliation>Department of Neurology, University of Turku, Turku, Finland</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">Parkinson's disease</keyword><keyword xml:id="k2">early treatment</keyword><keyword xml:id="k3">new strategies</keyword><keyword xml:id="k4">selegiline</keyword><keyword xml:id="k5">dopamine agonist</keyword><keyword xml:id="k6">levodopa</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><p>Over recent years I have been studying whether dopamine agonist treatment alone, or in early combination with levodopa, might institute a better long‐term treatment in Parkinson's disease than levodopa alone. Indeed, early combination of levodopa with bromocriptine, pergolide or lisuride has indicated that this kind of treatment results in better management of Parkinson's disease with fewer fluctuations in disability, especially end‐of‐dose disturbances and dyskinesias, than treatment with levodopa alone. Furthermore, similar results were obtained by using lisuride in combination with selegiline and levodopa. However, during long‐term treatment the changes in parkinsonian disability were equal in all treatment groups with or without selegiline. Thus, the possible efficacy of selegiline in slowing down the progression of Parkinson's disease requires further investigations. As a new treatment strategy it appears advisable to initiate the dopaminergic treatment in early Parkinson's disease by using initially selegiline and a dopamine agonist and by adding levodopa when the therapeutic response is insuifficient. Another alternative would be to start with selegiline alone, then add a dopamine agonist and, finally, levodopa.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>New strategies in the treatment of early Parkinson's disease</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>New strategies in the treatment of early Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">U. K.</namePart><namePart type="family">Rinne</namePart><affiliation>Department of Neurology, University of Turku, Turku, Finland</affiliation><description>Correspondence: Urpo K, Rinne, Department of Neurology, University of Turku SF‐20520 Turku, Finland</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">1991-10</dateIssued><copyrightDate encoding="w3cdtf">1991</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="references">26</extent></physicalDescription><abstract lang="en">Over recent years I have been studying whether dopamine agonist treatment alone, or in early combination with levodopa, might institute a better long‐term treatment in Parkinson's disease than levodopa alone. Indeed, early combination of levodopa with bromocriptine, pergolide or lisuride has indicated that this kind of treatment results in better management of Parkinson's disease with fewer fluctuations in disability, especially end‐of‐dose disturbances and dyskinesias, than treatment with levodopa alone. Furthermore, similar results were obtained by using lisuride in combination with selegiline and levodopa. However, during long‐term treatment the changes in parkinsonian disability were equal in all treatment groups with or without selegiline. Thus, the possible efficacy of selegiline in slowing down the progression of Parkinson's disease requires further investigations. As a new treatment strategy it appears advisable to initiate the dopaminergic treatment in early Parkinson's disease by using initially selegiline and a dopamine agonist and by adding levodopa when the therapeutic response is insuifficient. Another alternative would be to start with selegiline alone, then add a dopamine agonist and, finally, levodopa.</abstract><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>early treatment</topic><topic>new strategies</topic><topic>selegiline</topic><topic>dopamine agonist</topic><topic>levodopa</topic></subject><relatedItem type="host"><titleInfo><title>Acta Neurologica Scandinavica</title></titleInfo><genre type="Journal">journal</genre><identifier type="ISSN">0001-6314</identifier><identifier type="eISSN">1600-0404</identifier><identifier type="DOI">10.1111/(ISSN)1600-0404</identifier><identifier type="PublisherID">ANE</identifier><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>84</number></detail><detail type="issue"><caption>no.</caption><number>S136</number></detail><extent unit="pages"><start>95</start><end>98</end><total>4</total></extent></part></relatedItem><identifier type="istex">606CF73F0EA47D7B6C3F1CDA414B291234905B43</identifier><identifier type="DOI">10.1111/j.1600-0404.1991.tb05028.x</identifier><identifier type="ArticleID">ANE95</identifier><accessCondition type="use and reproduction" contentType="copyright">1991 Blackwell Munksgaard</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C19 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002C19 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:606CF73F0EA47D7B6C3F1CDA414B291234905B43
|texte= New strategies in the treatment of early Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |